Home > Search Results
  • We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
  • Added to PubMed Health

    clear
    • Custom range...

Treats neovascular (wet) age-related macular degeneration (AMD) and macular edema after retinal vein occlusion.

UsesSide effectsLatest evidence reviewsResearch summaries for consumersBrand names

Results: 13

Age-related macular degeneration: What are the advantages or disadvantages of aflibercept (Eylea)?

The drug aflibercept (trade name: Eylea) was approved in Germany in November 2012 for the treatment of neovascular (wet) age-related macular degeneration (AMD) in adults. Due to a lack of suitable data, it is not clear whether it has advantages or disadvantages compared with the current standard therapy.

Informed Health Online [Internet] - Institute for Quality and Efficiency in Health Care (IQWiG).

Version: July 18, 2013

Treatment-related mortality with aflibercept in cancer patients: a meta-analysis

PURPOSE: Aflibercept, a fully humanized vascular endothelial growth factor (VEGF)-targeted agent, has emerged as an effective therapy in the treatment of various solid tumors. We carried out an up-to-date meta-analysis to determine the risk of fatal adverse events (FAEs) in cancer patients treated with aflibercept.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2014

Risk of hypertension in cancer patients treated with aflibercept: a systematic review and meta-analysis

BACKGROUND: Aflibercept is currently approved as second-line treatment for patients with metastatic colorectal cancer, and its application in other types of tumors is undergoing clinical evaluation. Hypertension is one of its major adverse effects with a substantial variation in the reported incidences and has not been systematically investigated.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2014

Treatments for macular oedema following central retinal vein occlusion: systematic review

OBJECTIVES: To review systematically the randomised controlled trial (RCT) evidence for treatment of macular oedema due to central retinal vein occlusion (CRVO).

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2014

Comparative effectiveness of anti-VEGF agents for diabetic macular edema

OBJECTIVES: The aim of this study was to evaluate the comparative effectiveness of anti-vascular endothelial growth factor therapy in the treatment of diabetic macular edema (DME).

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2013

Efficacy and safety of intravitreal therapy in macular edema due to branch and central retinal vein occlusion: a systematic review

BACKGROUND: Intravitreal agents have replaced observation in macular edema in central (CRVO) and grid laser photocoagulation in branch retinal vein occlusion (BRVO). We conducted a systematic review to evaluate efficacy and safety outcomes of intravitreal therapies for macular edema in CRVO and BRVO.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2013

Current treatments in diabetic macular oedema: systematic review and meta-analysis.

OBJECTIVES: The aim of this systematic review is to appraise the evidence for the use of anti-VEGF drugs and steroids in diabetic macular oedema (DMO) as assessed by change in best corrected visual acuity (BCVA), central macular thickness and adverse events

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2013

A meta-analysis of anti-vascular endothelial growth factor remedy for macular edema secondary to central retinal vein occlusion

BACKGROUND: Central retinal vein occlusion (CRVO) associates with severe vision outcome and no proven beneficial treatment. Our meta-analysis intended to appraise the efficacy and safety of anti-vascular endothelial growth factor (anti-VEGF) agents in macular edema (ME) following CRVO.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2013

Antiangiogenic therapy for diabetic macular oedema

Diabetic macular oedema (DMO) is a common complication of diabetic retinopathy. The retina at the macula thickens and this can cause gradual loss of central vision. Grid or focal laser photocoagulation is effective in treating DMO and has been used for several years, but vision is rarely improved. Antiangiogenic therapy with anti‐vascular endothelial growth factor (anti‐VEGF) modalities has recently been proposed to try to improve vision in people with DMO. Anti‐VEGF drugs are delivered by an injection in the vitreous cavity of the eye and need to be repeated for maintenance.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2013

Anti‐vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion

We reviewed the evidence about the effect of anti‐vascular endothelial growth factor (anti‐VEGF) agents in people with macular oedema secondary to central retinal vein occlusion (CRVO).

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2014

Colon Cancer Treatment (PDQ®): Health Professional Version

Expert-reviewed information summary about the treatment of colon cancer.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: June 5, 2014

A Systematic Review of Intravitreal Bevacizumab for the Treatment of Diabetic Macular Edema [Internet]

Diabetic retinopathy (DR) and diabetic macular edema (DME) are microvascular complications of diabetes that are a leading cause of blindness in the diabetic population. DME — which is swelling of the retina due to leakage of fluid from blood vessels within the macula, the central portion of the retina — may occur at any time during the progression of DR. The goal of treatment is to preserve current visual acuity and reduce the chances of progression to visual loss. Successful laser treatment reduces moderate visual loss but has limited effects on improving visual acuity. Intravitreal injection of corticosteroids, such as triamcinolone acetate, may also moderately improve visual acuity, but these generally offer only short-term improvements in acuity in cases of DME refractory to laser treatment. Moreover, triamcinolone is not licensed by Health Canada for this indication. Ranibizumab is a recombinant humanized monoclonal immunoglobulin G1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF). It is the only pharmacological therapy licensed in Canada for the treatment of DME.

Rapid Response Report: Peer-Reviewed Summary with Critical Appraisal - Canadian Agency for Drugs and Technologies in Health.

Version: May 2012
Show search results within this document

Colorectal Cancer: The Diagnosis and Management of Colorectal Cancer

This guideline is relevant to all healthcare professionals who come into contact with patients with colorectal cancer or suspected of having colorectal cancer, as well as to the patients themselves and their carers. It is also expected that the guideline will be of value to those involved in clinical governance in both primary and secondary care to help ensure that arrangements are in place to deliver appropriate care for the population covered by this guideline.

NICE Clinical Guidelines - National Collaborating Centre for Cancer (UK).

Version: November 2011
Show search results within this document

Systematic Reviews in PubMed

See all (31)...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...